Table 1 Baseline demographics, laboratory values, selected treatment and outcomes for the total cohort, those who received immunosuppression and those who did not

Age

49.3 (+/- 17.9)

52.7 (+/- 18.7)

46.7 (+/- 17.0)

0.118

Male

53 (60.9)

24 (64.9)

29 (58)

0.516

White ethnicity

75 (86.2)

33 (89.2)

42 (84)

0.488

Diabetes

8 (9.2)

3 (8.1)

5 (10)

0.651

Hypertension

46 (52.9)

19 (51.4)

27 (54)

0.648

Cardiovascular disease

13 (15.1)

3 (8.1%)

10 (20)

0.124

Systolic BP at biopsy, mmHg

130 (120- 140)

130 (120 -140)

128 (119 – 135)

0.627

Diastolic BP at biopsy, mmHg

79.3 (11.5)

80.1 (+/-13.2)

78.7 (+/-10.0)

0.594

Creatinine, µmol/L

135 (90-218)

134 (96.8 – 227)

134 (88 – 201)

0.874

eGFR, ml/min/1.73m²

46 (27 – 76)

42.5 (25 – 71.3)

46 (28.5 – 70)

0.874

uPCR, mg/mmol

573 (210 – 811)

795 (627 – 998)

318 (193 – 692)

<0.001

Haemoglobin, g/L

124 (110 – 144)

118 (104 – 132)

125 (110 – 153)

0.012

Corrected calcium, mmol/L

2.32 (2.24 – 2.42)

2.30 (2.22 -0 2.39)

2.37 (2.30 – 2.46)

0.26

Phosphate, mmol/L

1.23 (1.05 – 1.37)

1.30 (1.17 – 1.39)

1.17 (1.04 – 1.33)

0.039

Albumin, g/L

33 (23-41)

23 (19.5 – 29.3)

40 (33 – 43)

<0.001

Presented with nephrotic syndrome

29 (33.3)

25 (67.6)

4 (4.6)

<0.001

Remission

Partial

20 (23)

8 (21.6)

12 (24)

0.794

Complete

43 (49.4)

23 (62.2)

20 (40)

0.041

Combined

63 (72.4)

31 (83.8)

32 (64)

0.041

Time to remission (days)

523 (159-1231)

191 (103.5 – 598)

806 (255 – 1677)

0.001

Relapse

29 (33.7)

18 (48.6)

11 (22)

0.027

ACEi/ ARB

67 (79)

28 (75.7)

39 (78)

0.799

Immunosuppression

37 (42.5)

-

-

-

RRT^a

Total

24 (27.6)

10 (27)

14 (28)

0.920

5 year

15 (17.2)

7(18.9)

8 (16)

0.722

10 year

22 (25.3)

9 (24.3)

13 (26)

0.859

Mortality^a

Total

24 (27.6)

10 (27)

14 (28)

0.920

5 year

9 (10.3)

5 (13.5)

4 (8)

0.404

10 year

17 (19.5)

6 (16.2)

11 (22)

0.501

Follow up duration, months

91 (39 – 129)

99 (37 – 137)

108 (57.5 – 140)

0.810